Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

Virpax Pharmaceuticals will present virtually at the H.C. Wainwright BioConnect Virtual Conference from January 10 to January 13, starting at 7:00 a.m. ET. CEO Anthony Mack will lead the presentation, with one-on-one meetings available on January 10 and 11. Participants can watch the presentation on-demand daily until 7:00 p.m. ET and access a replay for 90 days on the company’s website. Virpax focuses on non-addictive pain management and neurological disorders, aiming for FDA approval of several innovative drug delivery systems.

BERWYN, Pa.--(BUSINESS WIRE)-- Virpax^® Pharmaceuticals, Inc. (“Virpax”), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, January 10^th through Thursday, January 13^th starting at 7:00 a.m. ET. Anthony Mack, Chairman & CEO of Virpax, will be giving the presentation. Management will also be hosting virtual one-on-one meetings on Monday, January 10^th and Tuesday, January 11^th.

Event: Virpax Pharma Presentation at the H.C. Wainwright BioConnect Virtual Conference
Date: Monday, January 10^th through Thursday, January 13^th
Time: On Demand from 7:00 a.m. ET to 7:00 p.m. ET daily
Webcast: Register Here

A replay of the presentation will also be available for 90 days on the Virpax website.

For more information on the H.C. Wainwright BioConnect Conference or to schedule a one-on-one meeting with Virpax management, please contact your conference representative or you may also email your request to betsy.brod@affinitygrowth.com or call (212) 661-2231.

About Virpax Pharmaceuticals

Virpax is developing branded product candidates for non-addictive pain management and neurological disorders using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval of its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal Molecular-Envelope Technology (MET) enkephalin formulation being developed for the management of acute and chronic pain, including pain associated with cancer, as well as post-traumatic stress disorder (PTSD) under the name PES200. MET technology is also used in AnQlar™, a candidate to inhibit viral replication caused by influenza or SARS-CoV-2. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults. For more information, please visit www.virpaxpharma.com.

About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005200/en/

Christopher M. Chipman, CPA

Chief Financial Officer

cchipman@virpaxpharma.com

(610) 727-4597

Or

Investor Relations:

Betsy Brod

Affinity Growth Advisors

betsy.brod@affinitygrowth.com

(212) 661-2231

Media:

Laura Radocaj

DGI

212-825-3210

Source: Virpax® Pharmaceuticals, Inc.

FAQ

When is Virpax Pharmaceuticals presenting at the H.C. Wainwright conference?

Virpax Pharmaceuticals will present from January 10 to January 13, starting at 7:00 a.m. ET.

Who will be presenting for Virpax Pharmaceuticals at the conference?

CEO Anthony Mack will be presenting for Virpax Pharmaceuticals at the conference.

How can I attend the Virpax Pharmaceuticals presentation?

You can register to attend the presentation virtually through the provided links on their website.

What is the focus of Virpax Pharmaceuticals?

Virpax Pharmaceuticals specializes in developing products for pain management, CNS disorders, and anti-viral indications.

How long will the Virpax Pharmaceuticals presentation be available for replay?

The presentation will be available for replay for 90 days on the Virpax website.

What innovative platforms is Virpax Pharmaceuticals seeking FDA approval for?

Virpax is seeking FDA approval for its patented drug delivery systems including Epoladerm, Probudur, and Envelta.

What is the stock symbol for Virpax Pharmaceuticals?

The stock symbol for Virpax Pharmaceuticals is VRPX.